Novo Nordisk Escalates False Advertising Battle Against Eli Lilly with Motion for Preliminary Injunction
The legal battle between the two giants of the GLP-1 obesity market, Novo Nordisk and Eli Lilly, has intensified significantly. Following its initial Lanham Act complaint filed on July 21, 2026, Novo Nordisk filed a formal motion for a preliminary injunction on August 14, 2026, in the U.S. District Court for the District of New Jersey. The motion seeks to immediately halt Eli Lilly's national advertising campaigns for Zepbound and Mounjaro while the underlying lawsuit proceeds. The court, presided over by Judge Zahid N. Quraishi, held a hearing to consider the motion on August 17, 2026, with a decision currently pending.
The Core Advertising Dispute
Novo Nordisk's legal action targets Eli Lilly’s nationwide television and social media campaigns, which compare Zepbound directly to Wegovy. The advertisements highlight clinical results from the SURMOUNT-5 head-to-head trial, showing that patients taking tirzepatide (Zepbound) lost an average of 50 pounds compared to 33 pounds for those taking semaglutide (Wegovy).
Novo Nordisk argues that this comparison is intentionally misleading and outdated because it pits the maximum dose of Zepbound (15 mg) against Wegovy's lower maintenance doses (1.7 mg and 2.4 mg). Crucially, Novo points out that the FDA approved a higher 7.2 mg dose of Wegovy in March 2026, which demonstrated nearly 19% average weight loss (approximately 47 pounds) in clinical trials. By omitting this higher-dose data and only mentioning its existence in a "vague, confusing, and nearly illegible" footnote, Novo alleges Lilly is deceptively presenting Zepbound as vastly superior.
John F. Kuckelman, Senior Vice President and Group General Counsel at Novo Nordisk, stated:
"Millions of Americans living with obesity and type 2 diabetes rely on these medicines. Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly’s medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true."
Eli Lilly's Defense
Eli Lilly has vigorously defended its advertising, asserting that its campaigns are truthful, transparent, and grounded in the best available scientific evidence. Lilly argues that SURMOUNT-5 and SURPASS-2 represent the only completed, randomized, head-to-head clinical trials directly comparing tirzepatide and semaglutide.
A spokesperson for Eli Lilly defended the company's position, stating:
"Head-to-head clinical trials are the strongest evidence for comparing medicines. SURMOUNT-5 and SURPASS-2 are the only head-to-head, randomized clinical trials directly comparing tirzepatide and semaglutide — and Novo Nordisk wants to stop Lilly from sharing their results. Novo Nordisk has never tested its highest doses of semaglutide against Lilly's tirzepatide medicines in any clinical trial; instead, it is using a lawsuit to advance comparisons it has never put to the test."
Market Implications
This high-stakes legal battle highlights how critical direct-to-consumer advertising has become in the $80+ billion GLP-1 market, where public perception drives massive commercial shifts. According to Eli Lilly's Q2 2026 earnings disclosures, the Zepbound and Mounjaro franchise captured 60.9% of the U.S. obesity and diabetes market by revenue, compared to Novo Nordisk's 38.8%. Because clinical trial timelines span many months, marketing claims and legal injunctions represent immediate levers for both companies to protect and expand their market share.